Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.43)
# 362
Out of 5,015 analysts
241
Total ratings
44.34%
Success rate
30.32%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $49.00 | +28.57% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $61.56 | +29.97% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $31.45 | +233.86% | 20 | Sep 5, 2025 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $118 | $66.23 | +78.17% | 21 | Sep 3, 2025 | |
| MNPR Monopar Therapeutics | Reiterates: Overweight | $74 | $87.82 | -15.74% | 2 | Aug 27, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $23 → $32 | $28.18 | +13.56% | 8 | Aug 6, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $6.07 | +81.22% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $11.01 | +163.40% | 3 | Jul 10, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $5.96 | +168.46% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $8.99 | +11.23% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $7.09 | +323.13% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $22.11 | +266.35% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.88 | +43.44% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $63.76 | +92.93% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.09 | +2,812.62% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.96 | +257.14% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $69.92 | +88.79% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.54 | +71.94% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $26.77 | +150.28% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $8.30 | +153.01% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $14.80 | +95.95% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.54 | +159.94% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.53 | +216.21% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.59 | +324.71% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.36 | +235.82% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.73 | +709.25% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.56 | +733.33% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.49 | +1,309.40% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.66 | +261.45% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.20 | +1,566.67% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.78 | +508.47% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.53 | +58,723.53% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $12.66 | +3,059.56% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.79 | +10,641.82% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.66 | +2,602.70% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.28 | +5,387.80% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.71 | +543.27% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.01 | +5,840.59% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.29 | +6,876.74% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.42 | +177,364.79% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.58 | +27,283.19% | 1 | Jan 9, 2020 |
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.00
Upside: +28.57%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $61.56
Upside: +29.97%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $31.45
Upside: +233.86%
PTC Therapeutics
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $66.23
Upside: +78.17%
Monopar Therapeutics
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $87.82
Upside: -15.74%
Rigel Pharmaceuticals
Aug 6, 2025
Maintains: Neutral
Price Target: $23 → $32
Current: $28.18
Upside: +13.56%
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $6.07
Upside: +81.22%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $11.01
Upside: +163.40%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.96
Upside: +168.46%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $8.99
Upside: +11.23%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $7.09
Upside: +323.13%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $22.11
Upside: +266.35%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.88
Upside: +43.44%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $63.76
Upside: +92.93%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.09
Upside: +2,812.62%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.96
Upside: +257.14%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $69.92
Upside: +88.79%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.54
Upside: +71.94%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $26.77
Upside: +150.28%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $8.30
Upside: +153.01%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $14.80
Upside: +95.95%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.54
Upside: +159.94%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.53
Upside: +216.21%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.59
Upside: +324.71%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.36
Upside: +235.82%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.73
Upside: +709.25%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.56
Upside: +733.33%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.49
Upside: +1,309.40%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.66
Upside: +261.45%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.20
Upside: +1,566.67%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.78
Upside: +508.47%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.53
Upside: +58,723.53%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $12.66
Upside: +3,059.56%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.79
Upside: +10,641.82%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.66
Upside: +2,602.70%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $3.28
Upside: +5,387.80%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.71
Upside: +543.27%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.01
Upside: +5,840.59%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.29
Upside: +6,876.74%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.42
Upside: +177,364.79%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.58
Upside: +27,283.19%